Inhibition of HBV gene expression and replication by stably expressed interferon-α1 via adeno-associated viral vectors

Journal of Gene Medicine

Volumn 10, Issue 6, 2008, Pages 619-627

  Li, Zhi ^a   Yao, Hong ^a   Ma, Yan ^b   Dong, Qingming ^b   Chen, Yangchao ^b   Peng, Ying ^c   Zheng, Bo Jian ^a   Huang, Jian Dong ^a   Chan, Chu Yan ^b   Lin, Marie C ^a   Sung, Joseph J ^b   Yuen, Kwok Yun ^a   Kung, Hsiang Fu ^b   He, Ming Liang ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Adeno associated virus; Gene therapy; Hepatitis B virus; Hydrodynamic transfection; Interferon 1

Indexed keywords

ALPHA1 INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PARVOVIRUS VECTOR; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE REPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC STABILITY; HEPATITIS B; HEPATITIS B VIRUS; HYDRODYNAMICS BASED TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS INHIBITION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; HEPATITIS B; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; IMMUNOTHERAPY; INTERFERON-ALPHA; MICE; VIRUS REPLICATION;

ADENO-ASSOCIATED VIRUS; HEPATITIS B VIRUS; MUS;

EID: 46649100904     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1174     Document Type: Article

References (68)

1. Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet 2003; 362: 2089-2094.
2. Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: current status. Am J Med 2005; 118: 1413.
3. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
4. Tang ZY, Yu YQ, Zhou XD, et al. Progress and prospects in hepatocellular carcinoma surgery. Ann Chir 1998; 52: 558-563.
5. Arauz-Ruiz P, Norder H, Robertson BH, et al. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; 83: 2059-2073.
6. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198: 489-503.
7. Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988; 69: 2575-2583.
8. Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81: 67-74.
9. Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 2003; 46: 329-338.
10. Norder H, Courouce AM, Coursaget P, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47: 289-309.
11. Dehesa-Violante M, Nunez-Nateras R. Epidemiology of hepatitis virus B and C. Arch Med Res 2007; 38: 606-611.
12. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8-32.
13. Guilhot F, Roy L, Guilhot J, et al. Interferon therapy in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 18: 585-603.
14. Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev 2007; 18: 459-471.
15. Lauria F, Forconi F. Towards the pharmacotherapy of hairy cell leukaemia. Expert Opin Pharmacother 2004; 5: 1523-1533.
16. Kremenchutzky M, Morrow S, Rush C. The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis. Expert Opin Drug Saf 2007; 6: 279-288.
17. Farrell R, Heaney D, Giovannoni G. Emerging therapies in multiple sclerosis. Expert Opin Emerg Drugs 2005; 10: 797-816.
18. Buti M, Esteban R. Drugs in development for hepatitis B. Drugs 2005; 65: 1451-1460.
19. Guan R. Treatment of chronic hepatitis B infection using interferon. Med J Malaysia 2005; 60(Suppl B): 28-33.
20. Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 2003; 51: 761-785.
21. Gattoni A, Parlato A, Vangieri B, et al. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts). Clin Ter 2006; 157: 377-386.
22. Meurs EF, Breiman A. The interferon inducing pathways and the hepatitis C virus. World J Gastroenterol 2007; 13: 2446-2454.
23. Palumbo E. PEG-interferon alfa-2b for acute hepatitis C: a review. Mini Rev Med Chem 2007; 7: 839-843.
24. Baker GE, Tyring SK. Therapeutic approaches to papillomavirus infections. Dermatol Clin 1997; 15: 331-340.
25. Rockley PF, Tyring SK. Interferons alpha, beta and gamma therapy of anogenital human papillomavirus infections. Pharmacol Ther 1995; 65: 265-287.
26. Tyring SK, Cauda R, Baron S, et al. Condyloma acuminatum: epidemiological, clinical and therapeutic aspects. Eur J Epidemiol 1987; 3: 209-215.
27. Nagabhushan TL, Maneval DC, Benedict WF, et al. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. Cytokine Growth Factor Rev 2007; 18: 389-394.
28. Tsukuma H, Tanaka H, Ajiki W, et al. Liver cancer and its prevention. Asian Pac J Cancer Prev 2005; 6: 244-250.
29. Vannucchi S, Chiantore MV, Mangino G, et al. Perspectives in biomolecular therapeutic intervention in cancer: from the early to the new strategies with type I interferons. Curr Med Chem 2007; 14: 667-679.
30. Vitale G, van Eijck CH, van Koetsveld Ing PM, et al. Type 1 interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg 2007; 246: 259-268.
31. Ishikawa T, Kono D, Chung J, et al. Polyclonality and multispecificity of the CTL response to a single viral epitope. J Immunol 1998; 161: 5842-5850.
32. Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
33. Liu CJ, Chen PJ, Lai MY, et al. Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba. Antivir Ther 2004; 9: 895-903.
34. King JK, Yeh SH, Lin MW, et al. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: a pilot study. Hepatology 2002; 36: 1416-1424.
35. Mahmood S, Niiyama G, Kamei A, et al. Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int 2005; 25: 220-225.
36. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-1498.
37. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129.
38. Kao JH, Chen PJ, Lai MY, et al. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002; 40: 1207-1209.
39. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009-1013.
40. Rabinowitz JE, Samulski J. Adeno-associated virus expression systems for gene transfer. Curr Opin Biotechnol 1998; 9: 470-475.
41. Chen CC, Ko TM, Ma HI, et al. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Ther 2007; 14: 11-19.
42. Monahan PE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000; 6: 433-440.
43. Jiang H, Pierce GF, Ozelo MC, et al. Evidence of multi year factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 2006; 14: 452-455.
44. Streck CJ, Dickson PV, Ng CY, et al. Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta. Cancer Gene Ther 2006; 13: 99-106.
45. McPhee SW, Janson CG, Li C, et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006; 8: 577-588.
46. Grieger JC, Samulski RJ. Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications. Adv Biochem Eng Biotechnol 2005; 99: 119-145.
47. Le Bec C, Douar AM. Gene therapy progress and prospects - vectorology: design and production of expression cassettes in AAV vectors. Gene Ther 2006; 13: 805-813.
48. Ladner SK, Otto MJ, Barker CS, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 1997; 41: 1715-1720.
49. Yang PL, Althage A, Chung J, et al. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 2002; 99: 13825-13830.
50. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541.
51. Auricchio A, Hildinger M, O'Connor E, et al. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 2001; 12: 71-76.
52. Li XP, Li CY, Li X, et al. Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus-mediated expression of human endostatin. Mol Cancer Ther 2006; 5: 1290-1298.
53. He M, Wen L, Campbell CE, et al. Transcription repression by Xenopus ET and its human ortholog TBX3, a gene involved in ulnar-mammary syndrome. Proc Natl Acad Sci USA 1999; 96: 10212-10217.
54. He ML, Wu J, Chen Y, et al. A new and sensitive method for the quantification of HBV cccDNA by real-time PCR. Biochem Biophys Res Commun 2002; 295: 1102-1107.
55. Chen Y, Du D, Wu J, et al. Inhibition of hepatitis B virus replication by stably expressed shRNA. Biochem Biophys Res Commun 2003; 311: 398-404.
56. Xu R, Sun X, Tse LY, et al. Long-term expression of angiostatin suppresses metastatic liver cancer in mice. Hepatology 2003; 37: 1451-1460.
57. Matskevich AA, Cordelier P, Strayer DS. Conditional expression of IFN-alpha and IFN-gamma activated by HBV as genetic therapy for hepatitis B. J Interferon Cytokine Res 2003; 23: 709-721.
58. Berraondo P, Ochoa L, Crettaz J, et al. IFN-alpha gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes. Mol Ther 2005; 12: 68-76.
59. Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93: 557-564.
60. Ohashi K, Nakai H, Couto LB, et al. Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver. Hum Gene Ther 2005; 16: 299-306.
61. Kawanishi Y, Hayashi N, Katayama K, et al. Tumor necrosis factor-alpha and interferon-gamma inhibit synergistically viral replication in hepatitis B virus-replicating cells. J Med Virol 1995; 47: 272-277.
62. Clarke CJ, Trapani JA, Johnstone RW. Mechanisms of interferon mediated anti-viral resistance. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1: 117-130.
63. Ma Y, Chan CY, He ML. RNA interference and antiviral therapy. World J Gastroenterol 2007; 13: 5169-5179.
64. Wu HL, Huang LR, Huang CC, et al. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology 2005; 128: 708-716.
65. Tu SP, Cui JT, Liston P, et al. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala. mutant. Gastroenterology 2005; 128: 361-375.
66. Wang L, Tang ZY, Qin LX, et al. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 2000; 32: 43-48.
67. Tang ZY, Ye SL, Liu YK, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 187-196.
68. Craxi A, Antonucci G, Camma C. Treatment options in HBV. J Hepatol 2006; 44: S77-S83.